Rural vs. urban disparities in association with lower urinary tract symptoms and benign prostatic hyperplasia in ageing men, NHANES 2001–2008
Summary Objective The objective of this study was to investigate rural/urban and socio‐demographic disparities in lower urinary tract symptoms and benign prostatic hyperplasia (LUTS/BPH) in a nationally representative population of men. Methods Data on men age ≥40 years (N = 4,492) in the 2001‐2008...
Saved in:
Published in | International journal of clinical practice (Esher) Vol. 69; no. 11; pp. 1316 - 1325 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Hindawi Limited
01.11.2015
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Summary
Objective
The objective of this study was to investigate rural/urban and socio‐demographic disparities in lower urinary tract symptoms and benign prostatic hyperplasia (LUTS/BPH) in a nationally representative population of men.
Methods
Data on men age ≥40 years (N = 4,492) in the 2001‐2008 National Health and Nutrition Examination Surveys were analysed. Self‐report of physician‐diagnosed enlarged prostate and/or BPH medication use defined recognised LUTS/BPH. Urinary symptoms without BPH diagnosis/medications defined unrecognised LUTS/BPH. Rural–Urban Commuting Area Codes assessed urbanisation. Unadjusted and multivariable associations (odds ratios (OR)) between LUTS/BPH and covariates were calculated using logistic regression.
Results
Recognised and unrecognised LUTS/BPH weighted‐prevalence estimates were 16.5% and 9.6%. There were no significant associations between LUTS/BPH and rural/urban status. Significant predisposing factors for increased adjusted odds of recognised and unrecognised LUTS/BPH included age, hypertension (OR=1.4;1.4), analgesic use (OR=1.4;1.4) and PSA level >4 ng/mL (OR=2.3;1.9) when adjusted for rural/urban status, race, education, income, alcohol, health insurance, health care and proton pump inhibitor (PPI) use (all p ≤ 0.1). Restricting to urban men only (N = 3,371), healthcare use (≥4visits/year) and PPI's increased adjusted odds of recognised LUTS/BPH (OR=2.0;1.6); no health insurance and <high school education decreased odds (OR=0.5;0.6) after adjusting for variables listed above, antidepressant and calcium channel blocker use (p ≤ 0.1). Also among urban men, adjusted odds of unrecognised LUTS/BPH increased for blacks (OR=1.9), Hispanic/Other (OR=1.9) and income<$34,999 (OR=1.6). Among rural men only (N = 1,121), adjusted odds of recognised and unrecognised LUTS/BPH increased for age, hypertension (OR=1.9;1.7) and analgesic use (OR=2.0;1.5) when adjusting for race, CRP, antidepressant and dyslipidaemic use (p ≤ 0.1).
Conclusion
Rural/urban status was not associated with significantly increased adjusted odds of either recognised or unrecognised LUTS/BPH. |
---|---|
Bibliography: | Disclosure The findings and conclusions in this manuscript are those of the authors and do not necessarily represent the views of the Research Data Center, the National Center for Health Statistics, or the Centers for Disease Control and Prevention. Data collection for the 2001–2008 National Health and Nutrition Examination Surveys was approved by the NCHS Research Ethics Review Board. Analysis of de‐identified data from the survey is exempt from the federal regulations for the protection of human research participants. Analysis of restricted data through the NCHS Research Data Center is also approved by the NCHS ERB. Kathryn B. Egan, PhD, MPH, and Minhyung Suh, MPH are employees of New England Research Institutes, Inc. Arthur L. Burnett, MD, MBA,FACS receives research funding from Endo Pharmaceuticals, Pfizer, the National Institutes of Health, Auxilium Inc, American Medical Systems, Coloplast, Reflexonic LLC, Vivus, Acorda Therapeutics, and Medispec; is on the advisory board for The Center for Intimacy after Cancer Therapy; is a consultant to Genomic Health Inc and the New England Research Institutes; and is on the editorial board for Vivus, Journal of Sexual Medicine, Andrology, International Urology and Nephrology, Practical Reviews in Urology and European Urology. Xiao Ni, PhD, and David G. Wong, MD are employees and stock holders of Eli Lilly and Company. Raymond C. Rosen, PhD, is an employee of New England Research Institutes, Inc. and receives research funding from Eli Lilly and Company and Bayer Healthcare. Kevin T. McVary, MD, FACS, receives research funding from Allergan, Eli Lilly/ICOS, NxThera, Neotract, the National Institutes for Diabetes and Digestive and Kidney Diseases (NIDDK), Astellas, American Medical Systems and Sophris; is an advisor/consultant for Allergan, Eli Lilly/ICOS, NxThera, Watson Pharmaceuticals, Neotract and NIDDK; and has received speaker fees from GlaxoSmithKline. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1368-5031 1742-1241 |
DOI: | 10.1111/ijcp.12709 |